Synthetic Oncolytic LNP-Replicon RNA for Cancer Immunotherapy
Exclusively Licensed
Invention type: Technology
/
Case number: #21306HJQ
The present disclosure relates to synthetic oncolytic viruses comprising a lipid nanoparticle comprising one or more types of lipid and a self-amplifying replicon RNA comprising a sequence that encodes an immunomodulatory molecule.
Researchers
Darrell J Irvine
/
Noor Momin
/
Yingzhong Li
/
Yizhou Dong
/
Ron Weiss
/
Karl Dane Wittrup
Departments: Department of Biological Engineering, Department of Chemical Engineering
Technology Areas: Biotechnology: Synthetic Biology / Drug Delivery: Microparticles & Nanoparticles / Therapeutics: Nucleic Acids, Vaccines
Impact Areas: Healthy Living
-
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Hong Kong | Published application -
synthetic oncolytic lnp-replicon rna for cancer immunotherapy
United States of America | Granted | 11,717,548 -
synthetic oncolytic lnp-replicon rna uses for cancer immunotherapy
United States of America | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
New Zealand | Pending -
synthetic oncolytic lnp-replicon rna uses for cancer immunotherapy
United States of America | Published application -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Malaysia | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Australia | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Brazil | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Canada | Published application -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
China | Published application -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Colombia | Published application -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
European Patent Convention | Published application -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Israel | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
India | Published application -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Japan | Granted | 7,561,134 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Mexico | Published application -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Malaysia | Granted | 0 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
New Zealand | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Philippines | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Russian Federation | Granted | 2,809,724 -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Saudi Arabia | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Singapore | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Thailand | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Korea (south) | Published application -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
United Arab Emirates | Pending -
synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
Japan | Published application
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.